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Background: Successful implementation of newborn screening (NBS) for cystic fibrosis (CF) depends on robust protocols, good communication
and appropriate management of recognised infants. In response to current varied practice, the ECFS Neonatal Screening Working Group
developed a consensus on the early management of these infants using the Delphi methodology.
Methods: Following detailed literature review, statements were generated by a core group of experts and then assessed by a larger group using modified
Delphi methodology.
Results: Forty-one statements were written by the core group. Eighty-six CF specialists contributed to the modified Delphi process. During three
rounds, extra statements were added and consensus achieved on 44 (one statement did not achieve consensus).
Conclusions: These statements will provide a framework for the management of screened infants in the first year of life. This process highlights
the paucity of evidence on which to base management of these infants. To improve this situation, it is important that each infant with CF identified
through NBS has opportunity to be included in a randomised controlled trial.
Crown Copyright © 2010 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. All rights reserved.Keywords: Cystic fibrosis; Newborn screening; Delphi methodology; Guidelines; Infants; Management1. Introduction
The successful expansion of newborn screening for cystic
fibrosis (CF) across Europe has highlighted the need for clear
guidance on the management of screen-positive infants, based
on the best available evidence [1,2]. Current practice has
evolved through experiential knowledge and a previous survey
suggests wide variability across regions and countries [3]. There
is good evidence to support newborn screening as a valid
undertaking, particularly with respect to early nutritional
benefits [1,4–8] but the validity of screening is undermined if
appropriate management is not available [9].☆ Data presented at 32nd ECFS meeting, Brest, France: Sermet-Gaudelus I,
Mayell SJ, Southern KW. Towards a consensus on the early management of
infants identified with cystic fibrosis following newborn screening (NBS) J Cyst
Fibros 2009;8 suppl 2:S11 (abstract 41).
⁎ Corresponding author. Tel.: +44 151 2933536; fax: +44 151 2525456.
E-mail address: kwsouth@liv.ac.uk (K.W. Southern).
1569-1993/$ - see front matter. Crown Copyright © 2010 Published by Elsevier B
doi:10.1016/j.jcf.2010.04.008This project was undertaken under the auspices of the
European CF Society Neonatal Screening Working Group and
involved three stages: a review and grading of available evidence;
generation of draft guideline statements by a core group of experts
and, finally, review and modification of those statements through
a modified Delphi consensus process.
The Delphi methodology allows the development of a
consensus on actions when a lack of published evidence is
available to guide practice [10]. This methodology has been
recognised by numerous healthcare authorities, including the
World Health Organisation, as an important and valid technique
for establishing consensus. The strengths of the process are
inclusivity, relative anonymity (giving exposure to the quiet voice)
and economy (can be conducted primarily through email
correspondence). The drawbacks are that it is time consuming
and generates a large amount of data,which needs careful analysis.
The aim of this project was to produce evidence based
guidelines on the management during the first year of life of
infants with CF diagnosed through newborn screening..V. on behalf of European Cystic Fibrosis Society. All rights reserved.
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A list of topics was defined by a core group and a compre-
hensive search undertaken for published and unpublished
literature on these topics (IS). After completing this process
statements were generated and graded according to the recom-
mendations of the Scottish Intercollegiate Guidelines Network
(SIGN) (IS and KWS) [11].
These statements were then further reviewed and modified by
a core group of CF experts. Statements were divided into General,
Nutritional and Respiratory. Nutritional and Respiratory state-
ments were further divided into three classes of statement;
1) Monitoring, 2) Preventive and 3) Reactive.
All members of the European CF Society (ECFS) were
invited to contribute to the modified Delphi methodology. The
Delphi process was overseen by a facilitating group (IS, SM and
KWS). This group sought further advice from experts on
comments that arose during the Delphi process.
Inclusion was restricted to respondents in Europe and
Australasia, so as not to replicate work being undertaken for
North America (personal communication, P Farrell and D
Borowitz). In addition, health professionals from different
disciplines (for example, dietetics and physiotherapy) were
approached directly to ensure multidisciplinary representation.
Participants were sent the list of statements and asked whether
they agreed, disagreed or were unable to comment with each. If
they disagreed they were asked to provide a reason and/or an
alternative statement. References were also requested, in case
trials had been overlooked in the initial search strategy.
We determined that 80% agreement would determine an
adequate consensus on a statement [12]. However, even if
consensus was achieved, comments were still considered and
incorporated if it was felt by the facilitating group that they
significantly improved or clarified a statement.
There were three rounds for participants to comment on the
developing statements. For each round only statements that had
been altered from the previous round were considered. For
altered statements, participants received all the comments on the
statement and explanation as to why the statement had been
changed.
After Round 3, the statements were presented and discussed
at the annual Neonatal Screening Working Group meeting
(European CF Conference, Brest 2009).Fig. 1. The stages and outcomes of the modified Delphi method.3. Results
3.1. Literature review
The quantity and quality of published trials on the early
management of infants with CF were considered poor. Most
interventions were graded as D (evidence from published case
reports/series or expert opinion). Even when the level of evidence
was graded as 1+ with well conducted systematic reviews (for
example; anti-staphylococcal prophylaxis and physiotherapy in
the asymptomatic child), these were not able to provide clear
guidance on management.3.2. The modified Delphi process
The core group developed 41 statements, which were used in
RoundOne of themodifiedDelphi process (Fig. 1). Eighty-sixCF
specialists from Europe and Australia contributed to the modified
Delphi process. Consensus was not achieved on five statements,
which were modified in light of comments and suggestions. Four
new statements were added to reflect specific comments. Fifteen
statements were adjusted, despite achieving consensus, as the
facilitating group felt this improved the quality of the statement.
After the second round, five statements remained to achieve
consensus, but alterations for Round 3 enabled consensus to be
achieved on four of these outstanding statements. One statement
Table 2
Statements on nutritional management.
Monitoring nutrition and growth
11 Weight, length, and head-circumference should be measured at each
consultation and recorded on a growth chart with age specific percentiles.
12 Growth targets should reflect genetic potential, sibling height and local
population demographics.
13 At diagnosis, infants must have pancreatic function assessed clinically and
by measuring stool fecal elastase. Repeated assessment of pancreatic status
is essential during the first year of life if elastase is normal at diagnosis.
Preventive nutritional care
14 Breast feeding should be encouraged.
15 All infants with pancreatic insufficiency (PI) should be commenced on
pancreatic enzyme replacement therapy (PERT). Starting dose should be in the
region of 2000 IU lipase per 100 ml standard formula and then increased if
there are signs and/or symptoms of malabsorption or an inadequate rate of
weight gain.
16 Families of breast-fed infants should receive specific advice regarding
PERT, salt supplements and nutritional intake.
17 Infants that receive high doses of PERT (greater than 10000 IU kg−1 day−1
lipase) should be reviewed by an experienced CF dietician and/or a
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reiterations.
3.3. General statements
Several statementsweremodified to strengthen the importance
of their content by changing “should” to “must” following
analysis of respondents' comments and in line with other ECFS
consensus documents (Table 1). This was well received in Round
Two with higher levels of consensus achieved. Clarification that
the multidisciplinary teammust be paediatric followed comments
that in some countries the team would not automatically be the
case. Given the young age of patients diagnosed through
screening this was considered to be essential.
Statements describing the composition of themultidisciplinary
team, available resources and prevention of cross-infection were
well received with agreement of over 95% in Round One. Follow
up of the family with access to genetic counselling, education of
families, sweat testing of siblings and communication with
primary care achieved consensus levels between 87 and 100%.
A number of participants were concerned about a suggested
basic frequency of multidisciplinary review of 6–8 weeks. This
statement (number 6) was approaching consensus at 77%. After
changing the statement to every 4–8 weeks, 88% agreement was
achieved in Round 2.
A statement on accessibility of care was added in response to
comments from Round One. The initial statement suggested
that families should be able to contact the team at any time. This
provoked significant discussion but was approaching consensus
(74%). Local clinic resources and service structure obviously
determine the availability of the CF team particularly for out of
hours care. Modifying the statement to consider these factors,
consensus improved to 97% (Statement 9).
Statements concerning guidance on immunisations achieved
high levels of agreement (10, 37 and 38). These statements shouldTable 1
General statements.
1 Infants must receive care from a paediatric multidisciplinary team of CF
specialists (physician, nurse specialist, physiotherapist, dietician,
psychologist, and social worker).
2 Families should be offered access to genetic advice and counselling.
3 Siblings should be sweat-tested.
4 Infants should receive care in a centre with appropriate equipment and
resources to facilitate a level of care according to the guidelines.
5 Measures must be in place to prevent cross-infection.
6 Infants must be reviewed in clinic by the team every 4–8 weeks, and more
frequently after diagnosis or if there are any clinical concerns.
7 The CF team should communicate clearly and promptly with the primary
care team.
8 Education of the families must be implemented from diagnosis. Families
should have access to information so that they develop progressively a clear
understanding of CF care and what changes to expect as their child grows.
9 Families should be able to contact the CF team during normal working
hours. Specific arrangements should be in place for emergencies outside
working hours.
10 Parents should be encouraged to ensure their infant receives standard
childhood immunisations, according to national guidelines (see also
statements 37 and 38).be read in conjunction with the ECFS Vaccination Group
document “Immunisation in the current management of cystic
fibrosis patients” [13].
3.4. Nutritional management
The requirement for baseline nutritional assessment, together
with the content and timing of this provoked considerable
discussion (Table 2). Significant differences in local practice
exist. Some centres perform baseline assessment at first annual
review, some centres at diagnosis. The facilitating group
considered this a key statement; however we were unable to
obtain consensus even following three adaptations of the
statement reflecting comments. In fact, levels of agreementPaediatric Gastroenterologist with experience in CF.
18 There is no evidence to support the routine use of therapies to reduce gastric
pH in infants.
19 Energy intake should be adapted to achieve normal growth. Higher intake
(up to 150% of the dietary reference values for age) may be necessary.
20 There is no evidence to support the routine use of hydrolysed formula,
however, it may be of value for infants with non-CF malabsorption (short
bowel syndrome, post-infectious lactase deficiency, cholestatic liver
disease, and cow's milk protein intolerance).
21 Sodium chloride supplementation (2mmol kg−1 day− 1) should be
considered for all CF infants, and increased during periods of hot weather
and with other causes of high salt loss (for example, diarrhoea, fever and
ileostomy).
22 There is no evidence supporting oral supplementation of trace elements
beyond the age-appropriate recommended daily allowance.
23 Fat-soluble vitamins need to be supplemented routinely (Appendix A) in
infants with pancreatic insufficiency.
24 There is no agreement on the dose and preparation for Vitamin K
supplementation. ( Appendix A)
Reactive nutritional care
25 In infants with nutritional concern, dietetic review is essential. It should
prompt advice to increase calorie intake, review of PERT, and possibly
interventions to reduce gastric acidity.
26 If poor weight gain persists despite optimal PERT, other causes of poor
growth/malabsorption should be excluded.
Table 3
Statements on pulmonary disease management.
Monitoring pulmonary status
27 Infants should have a detailed clinical respiratory assessment at each clinic
visit ( Appendix B).
28 Evidence of respiratory infection (cough, wheeze, increased work of
breathing, and added sounds on auscultation) must prompt respiratory
culture and additional antibiotic treatment.
29 Respiratory cultures should be performed at each visit, according to best
local practice.
30 Chest radiograph should be performed at baseline assessment following
diagnosis and if clinically indicated (persisting symptoms despite
treatment).
31 There is insufficient evidence to support routine High Resolution Computed
Tomography (HRCT) in the first year of life.
32 There is insufficient evidence to support routine Infant Pulmonary Function
Tests.
33 Bronchoalveolar lavage (flexible bronchoscopy) should be considered in
symptomatic infants not responding to standard therapies if routine cultures
are non-contributive.
34 If the infant remains symptomatic with persistently negative respiratory
cultures, other causes, especially Gastro-Oesophageal Reflux, should be
excluded.
35 Measuring Pseudomonas antibody levels may identify early airway
infection, but there is insufficient evidence and standardization of assays
to support routine testing in the first year of life.
Preventive pulmonary care
36 Techniques to facilitate airway clearance should be undertaken on a regular
basis. Debate exists as to the best strategy in asymptomatic infants.
37 Anti-influenza vaccination should be given after the age of 6 months (2
injections of 0.25 ml at 1 month interval)
38 RSV infection is considered an important factor inCF lung disease; however at
present there is insufficient evidence to support the routine use of passive
immunisation in the first year of life.
39 There is insufficient evidence to support the routine use of anti-
pseudomonal vaccination at present.
40 Anti-staphylococcal antibiotic prophylaxis may be indicated as it reduces
isolation of Staphylococcus aureus from respiratory cultures in the first year
of life but longer term clinical outcomes are not clear. This is an area of
debate, as studies have suggested a possible association between the use of
cefalexin and increased Pseudomonas aeruginosa infection.
Reactive respiratory care
41 Physiotherapy for airway clearance should be undertaken more frequently
in the symptomatic infant
42 Antibiotic treatment must be initiated following recognition of
Pseudomonas aeruginosa, even in the asymptomatic infant. For other
pathogens, there is less clear agreement and treatment should be guided by
local policies.
43 For Pseudomonas aeruginosa, this should be a protocol aimed at
eradication.
44 Intravenous antibiotics should be considered if the infant remains symptomatic
despite initial therapy or if respiratory cultures remain positive.
326 I. Sermet-Gaudelus et al. / Journal of Cystic Fibrosis 9 (2010) 323–329deteriorated with each revision (Appendix C). It was apparent at
an open meeting of the ECFS Neonatal Screening Working
Group (31st European CF conference, 2009) that disparate
views precluded consensus being achieved on this statement.
There was a good level of agreement with the statement that
encouraged breast feeding, consistent with WHO recommenda-
tions and the ECFS nutrition consensus (Statement 14, 92%
agreement). These families require specific advice regarding
pancreatic replacement therapy (PERT), sodium supplementation
and nutritional intake (Statement 16, 92% agreement). Routine
use of hydrolysed formula was not supported except in infants
who have malabsorption not directly related to CF (Statement 20,
98% agreement).
In northern Europe 95% of infants are pancreatic insufficient
(PI) by 1 year of age [14]. However a significant number of
screened infants may be pancreatic sufficient (PS) at diagnosis
[15]. Whilst there is a lack of clear data the implication is that a
proportion of PS infants will become PI over the course of the first
year of life. In support of this, a study of NBS CF infants in
Northern Italy and Sydney, Australia, demonstrated 80/315
infants to be PS shortly after diagnosis. Twenty of these PS infants
then became PI over a median of 12 months (determined through
clinical features, fecal fat measurement and pancreatic stimulation
tests) [16]. Statement 13 advises initial assessment of pancreatic
function and then repeated assessment if fecal elastase is within
the normal range at diagnosis (83% agreement).
Calculating the dose of PERT in infants can be complex, there
is a lack of evidence examining the co-efficient of fat absorption
in this age group and dosing will depend on residual pancreatic
function which will vary between infants and may alter over time
in an individual infant [15]. These differences are reflected in the
variety of practice across Europe and the number of suggestions
and comments on Statement 15. This statement had particularly
useful input from senior dietitians. Best agreement (91%) was
achieved in Round Three when a minimum starting dose was
suggested rather than a dosing range. It should be highlighted that
this is a minimum starting dose and there must be a low threshold
for increasing doses according to inadequate rate ofweight gain or
evidence of malabsorption. Other factors affecting weight gain
and malabsorption should also be considered (see Statements 25
and 26). The dosage should be adjusted for practical purposes
according to PERT preparation used.
Statement 15 refers to those infants receiving standard infant
formula; infants receiving breast milk should have individually
tailored advice regarding PERT and supplementation (Statement
16).
Infants on high doses of PERT need thorough review and
assessment (Statement 17). The initial statement, suggesting
involvement of a paediatric gastroenterologist failed to reach
consensus (67%). Regional practice varies but most respondents
felt strongly that the assessment was more appropriately
performed by experienced CF dietitian with the addition of a
paediatric gastroenterologist where necessary (85% agreement).
There appears to be considerable variation in practice with
respect to salt supplementation. The original statement suggested
routine supplementation in all infants and failed to reach
consensus at 61% agreement. Changing the statement to“consideration to sodium supplementation should be given in
all infants particularly in situations of increased salt loss”
improved the agreement and consensus was achieved (Statement
21, 91% agreement). Situations that might result in increased salt
loss are a warm climate and periods of ill health. Specific advice
should be given for breast feeding infants (Statement 16).
Table 4
Interventions that require clinical studies in infants with CF diagnosed following
newborn screening.
Intervention Current status of clinical trials
Salt supplementation None known
Vitamin K for bone disease None known
Palivizumab to prevent RSV infection in the
first year of life
Systematic review to be
published soon.
Long-term ursodeoxycholic acid to prevent CF
liver disease
None known
Early versus late pancreatic enzyme
replacement therapy
None known
HRCT to detect lung disease in early infancy Perth/Melbourne study nearing
completion
Regular flexible bronchoscopy in early infancy Sydney/Brisbane study nearing
completion
Regular infant pulmonary function tests London study recruiting
Anti-staphylococcal prophylaxis None known
Airway clearance techniques in infants None known
Anti-pseudomonal immunisation Results of phase 3 studies
awaited
Cystic Fibrosis Specialists who contributed to the consensus:
Arets Bert Wilhelmina Children's Hospital, Utrecht, Netherlands
Ballman Manfred* Medical School Hannover, Germany
Ball Rosemary St James University Hospital, Leeds,
United Kingdom
Barben Jürg Children's Hospital, St Gallen, Switzerland
Bellon Gabriel Hôpital Debrousse, Lyon, France
Benden Christian University Hospital Zurich, Switzerland
Blaikie Lesley Raigmore Hospital, NHS Highland Trust, Scotland,
United Kingdom
Brownlee Keith St James University Hospital, Leeds, United
Kingdom
Bryon Mandy Great Ormond Street Hospital, London, United
Kingdom
Burrows Elinor Royal Liverpool Children's Hospital, Liverpool,
United Kingdom
Bush Andrew Royal Brompton Hospital, London, United
Kingdom
Castellani Carlo Cystic Fibrosis Center, Azienda Ospedaliera Verona,
Verona, Italy
Conway Steven St James Hospital University Hospital, Leeds,
United Kingdom
Corbetta Carlo Laboratorio di Riferimento regionale, Ospedale
dei Bambini, Milano, Italy
(continued on next page)
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Overall there were much better levels of agreement for
statements on pulmonary care (Table 3). Debate exists as to the
best strategy for airway clearance in infants, however Statement
36 recommended that this should be undertaken regularly
(regardless of technique) and achieved a good level of
agreement (88%).
The influenza vaccine was strongly supported (Statement 37,
96% agreement). There was also agreement that there was
insufficient evidence to support either passive RSV immunisa-
tion or anti-pseudomonal vaccines (Statements 38 and 39).
A significant area of debate was the use of routine measure-
ment of Pseudomonas antibodies to identify early airway
infection. The first suggestion was adapted to include some re-
cognition of the potential of this test, but reflected that insufficient
evidence and difficulties with standardization of assays did not
support routine testing in this age group. With these changes a
good level of agreement was achieved in Round Two (Statement
36, 90% agreement).
Some statements achieved adequate levels of agreement in
Round One but were adapted in Round Two to reflect comments.
For example, the Statement 40 regarding anti-staphylococcal
prophylaxis was made more informative and this improved the
level of agreement from 84% to 89%.
There was some disagreement with regard to antibiotic
treatment for the asymptomatic infant with a positive respiratory
culture. When this was specified as Pseudomonas aeruginosa,
levels of agreement improved (Statement 42, 91% agreement).
For other pathogens there is less clear agreement and teams
were advised to follow local policies.
4. Discussion
This process has resulted in 44 statements that guide the early
management of screened infants with CF. Over 86 CF specialists
from 19 different countries have contributed to these statements
through the modified Delphi methodology. Participants repre-
sented a number of disciplines including dietetics, physiotherapy,
genetics, nursing and medicine. Over the course of the three
rounds of consensus development, 660 comments were generated
by the participants and assessed by the facilitating group.
Statements developed by the core group were adjusted and
improved significantly through this process.
Good levels of agreement were achieved for all statements
except one, which did not achieve consensus despite numerous
reiterations. This statement examined the need for, timing and
content of a baseline nutritional assessment. Arguments against a
baseline assessment included a perceived lack of useful additional
information and the potential of distress for the infant and family (if
blood tests are involved). Arguments in favour of baseline
assessment are the early recognition of nutritional deficiencies
and electrolyte imbalance. A number of changes to the statement
were made reflecting comments received; however this resulted in
a reduction in agreement (Appendix C). Lack of agreement on this
issue was further illustrated by an open discussion at the 2009
ECFC workshop on newborn screening. There is good agreementon the need for some form of baseline assessment; the lack of
consensus reflects both the variability in local practice and strength
of conviction of individuals on this topic.We recommend therefore
that CF teams discuss these issues and reflect on their local practice.
Further research is needed to determine the most appropriate
strategy for monitoring nutritional progress in this cohort.
As newborn screening for CF becomes established across
most of Europe, these statements will guide early management.
This process has highlighted the urgent need for large
randomised controlled trials of interventions in this screened
population (Table 4). All infants with CF identified through
NBS should have opportunity to be included in such a study.
This process will be repeated in 2011 to ensure new sources of
evidence are incorporated into the guidelines.
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Dankert-Roelse Jeanette Atrium Medisch Centrum Parkstad, Heerlen,
Netherlands
De Boeck Kristiane University Hospital Gasthuisberg, Leuven, Belgium
Derichs Nico Cystic Fibrosis Center, Medizinische Hochschule,
Hannover, Germany
Desai Maya Birmingham Children's Hospital, Birmingham,
United Kingdom
Dodge John University of Wales, Swansea, United Kingdom
Doull Iollo Children's Hospital for Wales, Cardiff,
United Kingdom
Dubus Jean-Christophe Unité de Médecine Infantile & CRCM Pédiatrique,
CHU Timone-Enfants, Marseille, France
Duiverman Eric J Beatrix Children's Hospital/University Medical
Center Groningen, Netherlands
Ellemunter Helmut Cystic Fibrosis Center Innsbruck, Innsbruck
Medical University, Austria
Ellison Julie Mid Cheshire NHS Trust, United Kingdom
Farrell Phillip* University of Wisconsin, USA
Feilcke Maria Munich Cystic Fibrosis Centre, Germany
Foote Keith Royal Hampshire County Hospital, United Kingdom
Gartner Silvia Hospital Universitario Materno Infantil Vall
d'Hebron, Barcelona, Spain
Gursli Sandra Norwegian National Center for CF, Ulleval
University Hospital, Kirkev, Norway
Hammermann Jutta* Dresden Cystic Fibrosis Centre, Germany
Hatziagorou Elpis Cystic Fibrosis Unit, Aristotle University of
Thessaloniki, Greece
Havermans Trudy UZ Leuven, Belgium
Hendriks JJE MUMC, Maastricht, Netherlands
Høiby Niels Rigshospitalet, University of Copenhagen,
Denmark
Kashirskaya Nataliya Research Centre for Medical Genetics, Moscow,
Russia
Kavanagh Caroline Norfolk and Norwich University Hospital, United
Kingdom
Kollberg Hans Former director of Uppsala CF-center Sweden
Lannefors Louise Lund CF-centre, Lund University Hospital, Sweden
Lebecque Patrick Cliniques Universitaires St Luc - UCL, Bruxelles,
Belgium
Lenoir Gérard Necker-Enfants Malades Hospital, Paris, France
Littlewood Jim M Chairman Cystic Fibrosis Trust, United Kingdom
Lucidi Vincenzina Bambino gesù hospital, Roma, Italy
Malfroot Anne Universitar Zeikenhuis Brussel, Belgium
Maretti Tanja University Pediatric Clinic in Skopje, R. Macedonia
Marguet Christophe CHU-RouenHôpital CharlesNicolle, Rouen, France
McCabe Helen Newcastle Upon Tyne Hospitals, United Kingdom
Mehta Anil University of Dundee, Scotland, United Kingdom
Moeller Alexander University Children's Hospital, Zurich, Switzerland
Munck Anne AFDPHE, Paris, France
Nährlich Lutz Universitätsklinikum Erlangen, Germany
Nilsson Mikael Lund CF-centre, Lund University Hospital, Sweden
Nixon Wendy Birmingham Children's Hospital, Birmingham,
United Kingdom
Norek Aleksandra Department of Medical Genetics, Institute of
Mother and Child, Warsaw, Poland
Padoan Rita Cystic Fibrosis Service, Spedali Civili Brescia, Italy
Pollitt Rodney Sheffield Children's Hospital, Sheffield, United
Kingdom
Prasad Ammani Great Ormond Street Hospital, London, United
Kingdom
Proesmans Marijke University Hospital Leuven, Belgium
Rault Gilles CF Center, Roscoff, Nantes University Hospital,
France
Reid Alastair Royal Belfast Hospital for Sick Children, United
Kingdom
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Sammon Alec Lay representative, France
Sands Dorota* CF Center, Institute of Mother and Child, Warsaw,
Poland
Schuster Anje University of Duesseldorf, Germany
Schwarz Martin J Regional Molecular Genetics Service, St Mary's
Hospital, Manchester
Sermet-Gaudelus Isabelle* CRCM, Hopital Necker-Enfants Malades, Paris,
France
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Smyth Alan University of Nottingham, United Kingdom
Sommerburg Olaf Heidelberg Cystic Fibrosis Centre, Germany
Southern Kevin* University of Liverpool, United Kingdom
Staab Doris CF Centre Berlin, Germany
Storrosten Olav Ullevl University Hospital, Oslo, Norway
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School, Germany
Taccetti Giovanni CF Center Meyer Hospital, Florence, Italy
Taylor Chris Sheffield Children's NHS Foundation Trust,
United Kingdom
Tješić-Drinković Dorian University Hospital Center Zagreb, Zagreb, Croatia
Torresani Toni University Children's Hospital, Zurich,
Switzerland
Tsanakas John Cystic Fibrosis Unit, Aristotle University of
Thessaloniki, Greece
Van Steenbergen Marianne Den Bosch, Netherlands
Vavrova Vera CF Centre Prague, University Hospital Motol,
Czech Republic
Vernooij Annette* National Institute of Public Health, Bilthoven
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Watling Ruth Royal Liverpool Children's Hospital, United
Kingdom
Wilschanski Michael Hadassah University Hospital, Jerusalem, Israel
Wilcken Bridget Westmead Children's Hospital, New South Wales,
Australia
Wyatt Hilary Kings College Hospital, London, United Kingdom
*Members of the core group.
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Appendix A
Suggested daily doses for fat-soluble vitamins in infants less
than 1 year
Vitamin A 1500 IU
Vitamin E 40–50 IU
Vitamin D 400–800 IU
329I. Sermet-Gaudelus et al. / Journal of Cystic Fibrosis 9 (2010) 323–329Vitamin K a dose for Vitamin K supplementation in cystic
fibrosis is not established. Recommendations for infants range
from 0.3 to 1 mg daily dose [17].Appendix B
Respiratory assessment
a) History:
– new or increased cough
– new or increased wheeze
– poor feeding
– fever
– increased respiratory rate/breathlessness
b) Examination:
– respiratory rate
– use of accessory muscles/dyspnoea
– cough/wheeze/hyperinflation
– wheeze and/or crackles on auscultation
c) Pulse oximetry
d) Physiotherapy assessment
Appendix C
Statement examining baseline assessment— alterations and
levels of agreement
Round One (77% agreement)
After diagnosis, a baseline assessment is done that includes,
as a minimum, the following tests:
• Plasma fat-soluble vitamin levels
• Serum albumin.
• Serum liver function tests
• Serum and urine sodium.
• Full blood count and iron status.
These measurements must be repeated every year (more
frequently if clinical concern).
Round Two (74% agreement)
Within 3 months after diagnosis, a baseline assessment must
be done, that includes, as a minimum:
• Plasma fat-soluble vitamin levels
• Serum albumin and liver function tests
• Serum and urine sodium
• Full blood count
Round Three (68% agreement)
A baseline assessment should be performed according to
local practice; there is debate as to the timing and content of this
assessment.References
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